I hope you will enjoy our issue summing up the 2019 San Antonio Breast Cancer Symposium (SABCS), which took place last December 10-14.
Could we spare our patients surgery in case that high-performing imaging and biopsies confirm complete remissions? Can predictive gene assays totally replace clinical features in early breast cancer? Hormone replacement in post-menopausal women: is the ban about to be lifted? You will find very interesting studies talking about these questions in the following chapter.
Concerning treatment of active disease, you will find a second oral fluoropyrimidine, an oral taxane, pertuzumab joining the subcutaneous injectables, and new drugs for refractory metastatic HER2 breast cancers coming on the scene. The role of immunotherapy in triple-...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Anifrolumab succeeds in second phase 3 trial in SLE Next Article
Tamoxifen monotherapy may mean undertreatment for some luminal breast cancer patients »